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ABSTRACT
Background We analysed the impact of breastfeeding,
antiretroviral drugs and health service factors on
cumulative (6 weeks to 18 months) vertical transmission
of HIV (MTCT) and ‘MTCT-or-death’, in South Africa, and
compared estimates with global impact criteria to validate
MTCT elimination: (1) <5% final MTCT and (2) case
rate ≤50 (new paediatric HIV infections/100 000 live
births).
Methods 9120 infants aged 6 weeks were enrolled in
a nationally representative survey. Of 2811 HIV-exposed
uninfected infants (HEU), 2644 enrolled into follow-up (at
3, 6, 9, 12, 15 and 18 months). Using Kaplan-Meier
analysis and weighted survey domain-based Cox
proportional hazards models, we estimated cumulative
risk of MTCT and ‘MTCT or death’ and risk factors for
time-to-event outcomes, adjusting for study design and
loss-to-follow-up.
Results Cumulative (final) MTCT was 4.3% (95% CI
3.7% to 5.0%); case rate was 1290. Postnatal MTCT (>6
weeks to 18 months) was 1.7% (95% CI 1.2% to 2.4%).
Cumulative ‘MTCT-or-death’ was 6.3% (95% CI 5.5% to
7.3%); 81% and 62% of cumulative MTCT and ‘MTCT-or-
death’, respectively, occurred by 6 months. Postnatal
MTCT increased with unknown maternal CD4-cell-count
(adjusted HR (aHR 2.66 (1.5–5.6)), undocumented
maternal HIV status (aHR 2.21 (1.0–4.7)) and exclusive
(aHR 2.3 (1.0–5.2)) or mixed (aHR 3.7 (1.2–11.4))
breastfeeding. Cumulative ‘MTCT-or death’ increased in
households with ‘no refrigerator’ (aHR 1.7 (1.1–2.9)) and
decreased if infants used nevirapine at 6 weeks (aHR 0.4
(0.2–0.9)).
Conclusions While the <5% final MTCT target was
met, the case rate was 25-times above target. Systems are
needed in the first 6 months post-delivery to optimise HEU
health and fast-track ART initiation in newly diagnosed
mothers.
INTRODUCTION
Since 2002, the coverage and intensity of national
programmes to prevent vertical HIV transmission
(prevention of mother-to-child transmission—
PMTCT) have increased in high HIV prevalence,
low- and middle-income countries (LMICs). Early
and long-term triple antiretroviral therapy (ART)
among women living with HIV (WLHIV) in
research sites reduces vertical transmission of HIV
(MTCT), improving infant HIV-free survival up to
48 weeks.1–4 Consequently, in countries where 90%
of the world’s population of pregnant WLHIV
reside (global plan priority countries), lifelong
maternal ART, known as PMTCT Option B+, has
been introduced to reduce MTCT.5 Data from
national programmes have been skewed towards
measuring early (birth or 6 weeks postpartum)
PMTCT impact as early populations are easier to
access.6 7 Consequently, we know that intrauterine
MTCT (measured at birth) and 6-week MTCT can
be reduced to 0.9% and 1.1%, respectively.8
However, in LMICs where breastfeeding is norma-
tive, MTCT at the end of breastfeeding is mostly
modelled.9 A reliable measure of final MTCT (at
the end of breastfeeding) is imperative to validate
the elimination of MTCT (EMTCT) as a public
health problem.10 Two EMTCT impact criteria
have been identified for validation: (1) <5% final
MTCT in breastfeeding populations and (2) ≤50
new paediatric infections per 100 000 live births
by the end of breastfeeding (case rate). Both need
to be sustained for 1 year.10 Consequently, measur-
ing long-term outcomes of HIV-exposed infants
(HEI) is critical. In this paper, we report the impact
of breastfeeding, maternal ART and health service
factors on postnatal MTCT (>6 weeks to 18
months), cumulative (6 weeks to 18 months)
MTCTand ‘MTCT-or-death”.
METHODS
Study design and sample size
We conducted a prospective observational cohort
study. HEI were identified through infant HIV-
antibody testing (maternal HIV-antibody crosses
the placenta and is detectable in infants’ blood).
Enrolment occurred at 6 weeks (range 4–8 weeks)
postnatal age (baseline visit), as part of a nationally
representative, cross-sectional, early PMTCT effec-
tiveness survey (29 October 2012–31 May 2013)7 11:
2314 and 1097 HEI were required to estimate
Goga AE, et al. J Epidemiol Community Health 2020;74:1069–1077. doi:10.1136/jech-2019-213453 1069





















18-month cumulative MTCT and ‘MTCT-or-death’, respectively,
with a relative precision of 30%, design effect of 2 and assuming
30% loss to follow-up at 18 months.
Data collection methods
Nurse data collectors (DCs), trained on standardised procedures
over 5 days, collected data (October 2012–September 2014).
Mothers or caregivers and their infants were sampled system-
atically (in facilities with long immunisation queues) or consecu-
tively (in small facilities). Infants needing emergency care were
excluded. HIV-antibody–positive infants or infant born to
mothers who reported being HIV positive were tested for HIV
infection. The latter were recruited into follow-up at baseline.
Self-reported HIV-negative mothers whose infants tested HIV-
antibody–positive were also eligible for follow-up. DCs arranged
follow-up appointments coinciding with the child’s routine fol-
low-up visits, at 3, 6, 9, 12, 15 and 18 months, or until the child
died or for one visit after an infant’s HIV-positive diagnosis,
whichever came first. At each follow-up, DCs conducted struc-
tured face-to-face interviews, corroborated reported information
with patient-held routine infant Road-to-Health Cards/Booklets
(RTHB) and pictorial food-medication-hospitalisation study dia-
ries, and drew infant blood for HIV testing. Infant feeding ques-
tions evaluated the intake of individual items (yes/no response to
each) over the previous 24 hours and 7 days prior to these
24 hours (8-day recall in total). Data were captured on mobile
telephones and uploaded real-time onto a password-protected
web-based interface. Trained supervisors monitored fieldwork.
PMTCT national guideline context
From 1 April 2010 to 31March 2013, South Africa implemented
WHO PMTCT ‘Option A’ policy (pregnant WLHIV received
ART if CD4 cell count≤350 cells/mm3 or antiretroviral prophy-
laxis (ARVs) from 14 weeks’ gestation; HEI received nevirapine
(NVP) prophylaxis for 6 weeks if not breastfeeding or until 1
week post-breastfeeding cessation.)12 From 1 April 2013, South
African adopted WHO PMTCT ‘Option B’ policy (pregnant or
lactating WLHIV received ART lifelong if CD4 cell count ≤350
cells/mm3 or until 1 week post-breastfeeding cessation; HEI
received NVP prophylaxis for 6 weeks).13 National guidelines
recommended routine HIV virologic testing among HEI at 6
weeks post-delivery and 6 weeks post-breastfeeding cessation,
and HIV-antibody testing at 18 months post-delivery.
Study HIV testing procedures
At baseline, HEI were identified using HIV-antibody testing on
infant-dried blood spots (iDBS), at the National Institute for
Communicable Diseases (NICD), Johannesburg.7 11 Antibody-
positive specimens or specimens from infants whose mothers
reported being HIV positive were tested for HIV infection
using qualitative total nucleic acid (TNA) PCR (COBAS
AmpliPrep/COBAS TaqMan (CAP/CTM) Qualitative assay ver-
sion 1.0, Roche Diagnostics, Branchburg, NJ). At follow-up (3, 6,
9, 12 and 15 months), iDBS from HIV-exposed uninfected
(HEU) infants were tested using TNA HIV (PCR) (COBAS
AmpliPrep/COBAS TaqMan (CAP/CTM) Qualitative assay ver-
sion 1.0, Roche Diagnostics). At 18 months, one (if negative) or
two (if positive) serial rapid HIV tests performed by routine (not
study) nurses, as per routine protocol, identified HIV infection.
Until 31 March 2014, SD Bioline HIV 1/2 3.0 Test D3FK16 was
used as the first rapid test and First Response HIV 1–2.0 as the
second test. From 1 April 2014, Advanced Quality (Armada
Health (Pty)) and One Step Advanced Quality (Titma Health
(Pty)) were used as the first rapid test and Abon (Fit Healthcare
and Diagnostics (Pty)) as the second test. These tests all have
sensitivities and specificities ≥99%.
Ethics
The protocol was approved by the institutional review board of
the South African Medical Research Council (SAMRC) and
reviewed by the Centers for Disease Control and Prevention
(CDC), Atlanta. All mothers/caregivers signed informed consent.
Laboratory results were returned to mothers through routine
services, assisted by study staff as needed. During all study visits,
mother and infants not in care were referred to routine services.
No personal identifiers were included in study databases.
Data analysis
Data analysis was conducted using SAS version 9.4 2002–2012
by SAS Institute, Cary, NC, USA) and Stata 13. Infants identi-
fied as being HIV exposed and infected (HIV serology and
PCR positive) at baseline were included in the calculation of
cumulative (6 weeks to 18 months) MTCT and ‘MTCT-or-
death’ All analyses were weighted for population live births,
non-consent (mothers who did not consent to follow-up) and
loss to follow-up.
Risk of cumulative (6 weeks to 18 -months) MTCT
A competing risk model was performed to measure cumulative
MTCT (6 weeks to 18 months), with death as the competing risk.
At each time point, we calculated MTCTas the weighted propor-
tion of HEU infants whose iDBS was TNA PCR positive.
Additionally, we calculated interval-specific MTCT incidence
for ART use reported at 6 weeks and breastfeeding as a time-
dependent variable, using 8-day recall of infant feeding practices
from the day of interview.
Risk of cumulative (6 weeks to 18 months) ‘MTCT-or-death’
The time to first occurrence of either MTCT (HIV-positivity) or
death was used to estimate the cumulative incidence of ‘MTCT-
or-death’ (6 weeks to 18 months). A weighted Kaplan-Meier
analysis was conducted, and the 95% CIs were adjusted for
survey design effect. The design effect was that of a domain-
based survey logistic regressionmodel of ‘MTCTor death’within
the cohort up to 18 months.
Risk factors for postnatal (after 6 weeks to 18 months) MTCT and
cumulative (6 weeks to 18 months) ‘MTCT-or-death’
To evaluate risk factors for postnatal MTCT, we excluded infant
HIV infections measured at baseline (6 weeks). A survey-domain-
based Cox proportional hazards model with time-dependent and
time-independent covariates was used with finite sampling cor-
rection factor for the primary sampling unit (facilities). We tested
the widely known association between feeding practices and
infant outcome, and the potential association between maternal
ARTuse and infant outcome with postnatal (after 6 weeks to 18
months) MTCTas the main outcome. This analysis adjusted for
several factors: (1) maternal and infant characteristics (maternal
age, infant gender and infant NVP receipt), (2) health service
factors (hospital birth, mother tested for CD4 count and docu-
mentation of maternal HIV on the RTHB), and (3) socio-
economic status (access to piped water, toilet, refrigerator, trans-
port, food and maternal single status). Using 8-day recall, we
defined any breastmilk exposure as any infant ingestion of
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breastmilk at that specific time point; exclusive breastfeeding
(EBF) as breastmilk only with the exception of prescribed med-
icines or oral rehydration solution;mixed breastfeeding (MBF) as
breastmilk with nutritive or non-nutritive liquids or solids and no
breastfeeding (NBF) as no reported breastmilk ingestion.
Maternal ART exposure was defined as maternal self-reported
ARTuse at each follow-up point. The model for postnatalMTCT
(N=34 events) included maternal ARTas a time-dependent fac-
tor and EBF, MF or NBF, documented at baseline (6 weeks), to
capture the risk associated with early feeding practice, given that
most transmission occurred before 6 months post-delivery.
The final model for cumulative (6 weeks to 18 months)
‘MTCT-or-death’ (the inverse of HIV-free survival) included
ART and any breastmilk exposure (EBF, MBF, NBF) as time-
dependent variables, on our assumption that ART-use and feed-
ing practice throughout this period affects outcome. Cross-
tabulations of the time-dependent variables are presented to
describe the transitions in feeding practices and ARTover time.
ROLE OF THE FUNDING SOURCE
The South African National AIDS Council and Global Fund
funded the study without undue influence. CDC, UNICEF, the
NICD, and National Department of Health (NDOH) provided
funding and technical support for protocol development and
data analysis, mobile data collection, laboratory procedures and
study contextualisation, respectively, without undue influence.
The SAMRC provided infrastructural support and partial sup-
port for A Goga’s time.
RESULTS
Of 2878 HEI, 67 were HIV positive at 6 weeks post-delivery;
thus, 2811 HEU infants and their caregivers were eligible for
follow-up after 6 weeks. Of these, 167 (5.9%) caregivers refused
to participate in the follow-up visits (figure 1). Thus, 2644 infants
were enrolled for 18-month follow-up; 84.6% (2238) of enrolled
infants had at least one face-to-face postnatal follow-up, and 96%
(2538) were tracked for survival. The proportion of eligible
infants with interview and iDBS data at 3, 6, 9, 12, 15 and 18
months was 68%, 65%, 64% 68%, 66% and 71% (n=1797 at 18
months), respectively.
Eligible mothers who did not consent to infant follow-up were
less likely to receive maternal antiretroviral drugs (ARVs),
p<0.001, and were significantly younger (p=0.03) compared
with mothers who consented to follow-up. Mothers who con-
sented but did not return for infant follow-up were less likely to
receive maternal ARVs (p<0.001) and less likely to come from
Northern or Western Cape provinces. There were no significant
differences in feeding patterns at 6 weeks post-delivery between
infants included in this analysis and those excluded (no consent
for follow-up or lost to follow-up).
Infant feeding practices, maternal ART- and infant NVP-use
between 6 weeks and 18 months
The weighted prevalence of any breastfeeding decreased from
64.1% at 6 weeks, to 5.2% at 18months (figure 2 and online
supplementary table 1). The weighted prevalence of maternal
ART-use was 52.4% at 6 weeks and 59.5% at 18 months
(p>0.05 (figure 2 and online supplementary table 1). Infant NVP-
use among all infants was 93.2% (95% CI 91.8% to 94.7%) at 6
weeks decreasing to 3.1% (95% CI 2.3% to 3.9%), at 18 months
(figure 2 and online supplementary table 1). Among breastfeeding
infants, NVP use was 93.8% at 6 weeks, 85.4% at 3 months and
22.4% at 18 months (data not shown). Among breastfeeding
infants whose mothers were not on ART, a higher percentage
(96.7%, 95% CI 94.7% to 98.6%) were on NVP at 3 months,
decreasing to just below 70% by 12 months (data not shown).
Cumulative (6 weeks to 18 months) and postnatal (after 6
weeks to 18 months) MTCT
Cumulatively (6 weeks to 18 months), 101 HIV infections
were detected among HEI. Of these, 67 infant HIV infections
were detected at 6 weeks post-delivery and 34 were detected
during postnatal follow-up until 18 months. Using
a competing risk approach with death as the competing
risk, the cumulative MTCT risk (including the 6-week result)
was 4.3% (CI 3.7% to 5.0%) (figure 3 and online supplemen
tary table 2). Assuming an antenatal HIV prevalence of 30%,
this translates into a case rate of 1290 new paediatric infections
per 100 000 live births (30% maternal HIV prevalence×100
000 live births×4.3% MTCT at final endpoint). Among infants
who were HIV infected by 18 months (n=101), 60% of the
cumulative MTCT risk occurred by 6 weeks (range 4–8 weeks)
post-delivery; 81% occurred in the first 6 months post-delivery.
The postnatal (after 6 weeks to 18 months) MTCT risk was
1.7% (95% CI 1.2% to 2.4%). All infants with postnatal HIV
acquisition had breastmilk exposure before or at the time of
their HIV diagnosis. Twenty-two postnatally infected infants
had data on complete breastfeeding cessation. Of these, six
reported complete breastfeeding cessation to the yes/no ques-
tion, but all reported mixed feeding when specifically asked
about previous 8-day feeding practices at the visit prior to the
infant’s HIV diagnosis. Although 10 of the 22 HEI reported not
breastfeeding over the previous 8 days at the 6-week visit, 5
were mixed feeding at 3 months and tested HIV positive at 3
months. Only 1 of these 10 mothers was on ART. Two HEI
were also reportedly not breastfeeding at the time of infant HIV
diagnosis at 12 months (both last reported breastfeeding at 6
months), but both reported breastfeeding at 15 months. One of
the 22 breastfed at 6 weeks, 3, 9 and 15 months, with no
reported breastfeeding at 6 and 12 months, had equivocal
HIV test results at 6 weeks, 3, 6, and 12 months and tested
HIV positive at 15 months.
MTCT by feeding practice and ART group
Unadjusted interval-specific analysis relating MTCT to the
corresponding reported feeding practice demonstrated that
MTCT at baseline (6 weeks) was 4.7% (95% CI 2.8% to
8.9%) among mothers who reported MBF, 2.9% (95% CI
2.0% to 4.2%) among mothers reporting EBF and 1.3%
(95% CI 0.8% to 2.4%) among mothers reporting NBF
(table 1). Using 8-day recall data, we documented postnatal
MTCT among mothers who reported not breastfeeding
(table 1). The unadjusted risk of MTCT by ART initiation
period reported at 6 weeks was lowest among women who
initiated ART preconception (table 1). Numbers in these
breastfeeding and ART groups were too small for additional
modelling. Breastfeeding prevalence decreased approximately
fivefold, from 29.6% at 6 months to 5.2% at 18 months;
cumulative MTCT increased by approximately 0.2% every 3
months, and approximately 1.1-fold from 6 to 18 months
(3.9% at 6 months to 4.3% at 18 months).
‘MTCT or death’
For the composite outcome ‘MTCT-or-death’ (whichever came
first), 62 of 2644HEI died and 34 acquiredHIV between 6weeks
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and 18 months. Thirty of the 62 infants died before we deter-
mined their final HIV-status but were PCR negative at the last
visit. The weighted cumulative risk of ‘MTCT-or-death’ (6 weeks
to 18 months) was 6.3% (95% CI 5.5% to 7.3%) (figure 4A and
online supplementary table 3). Sixty-two per cent of cumulative
‘MTCT-or-death’ had occurred by 6 months post-delivery. After
the 6-week time point, ‘MTCT-or-death’ occurred in 3.7% of
infants (figure 4B and online supplementary table 3).
Infant age  >8-19 weeks: Interviewed n=1803 (68%)**
Missed visits n= 841
Infant age 20-31 weeks: Interviewed n=1709 (65%)** 
Missed visits n= 919
Infant age 32-44 weeks: Interviewed n=1673 (64%)**
Missed visits n= 931
Infant age 45-57 weeks: Interviewed n=1660 (68%)** 
Missed visits n= 919
HIV EIA negative n=6242
HIV PCR positive n=0 Died n= 11
HIV PCR positive  between >8-19 weeks  
n=  18 Infant died n= 2
Cohort Eligible EIA positive n=2878
6-week-old infant enrolled in SA PMTCT Evaluation six-week cross -sectional
survey + interviewed + EIA data available n=9120
HIV PCR positive between 20-31 weeks
n=  6 Died n= 16
HIV PCR positive between 32-44 weeks
n=  4 Died n= 20
HIV PCR positive between 45-57 weeks:
n= 4 Died n= 11
HIV PCR positive between 58-70 weeks     
n= 2 Died n= 218-months: Interviewed n= 1797 (71%)** 
Missed visits n= 764 
Infant HIV positive at 6-weeks n=67
Eligible for long-term follow-up: Infant EIA positive and 
not PCR positive n=2811
Infant age 58-70 weeks: Interviewed n=1680 (66%)** 
Missed visits n= 885
Enrolled for >6-weeks to 18-month follow-up 
n=2644 (94% of eligible)
Did not consent to follow-up n=167
Figure 1 Profile 2012–2014 study population.
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Risk factors for postnatal (6 weeks to 18 months) MTCT and
‘MTCT-or-death’
Time-dependent maternal ART use (time-dependent indicator)
was not significantly associated with postnatalMTCTor ‘MTCT-
or-death’, adjusted HR (aHR)=0.6 (95% CI 0.3 to 1.2) and 0.8
(95% CI 0.6 to 1.2), respectively (table 2). The risk of postnatal
MTCT significantly increased if the mother did not receive her
CD4 cell count result (aHR=2.7 (95% CI 1.5 to 5.6)), if there
was no documentation of infant HIV-exposure on the RTHB,
aHR=2.2 (95% CI 1.0 to 4.7), or if the infant reported mixed
feeding or EBF at 6 weeks using 8-day recall data (aHR=3.7
(95% CI 1.2 to 11.4), and 2.3 (95% CI 1.0 to 5.2), respectively)
(table 2). However, mixed feeding and breastfeeding were not
significant risk factors for ‘MTCT-or-death’, aHR 0.9 (95% CI
0.6 to 1.3) and aHR 1.6 (95% CI 0.8–2.9), respectively.
‘MTCT-or-death’ was significantly increased in households
without a refrigerator’ (aHR=1.74 (95%CI 1.06 to 2.88)), and
significantly decreased by infant NVP use at 6 weeks (aHR=0.4
(95% CI 0.18 to 0.88)) (table 2).
DISCUSSION
We demonstrate that cumulative (6 weeks to 18 months) MTCT
and ‘MTCT-or-death’was 4.3% (95%CI 3.7% to 5%) and 6.3%
(95% CI 5.5% to 7.3%), respectively, in the South African
national PMTCT programme by 2014. While this meets the
<5% WHO final MTCT impact criterion, the 30% antenatal
HIV prevalence14 translates into a case rate of 1290 new paedia-
tric HIV infections per 100 000 live births—more than 25 times
the target. In previous analyses, we demonstrated that maternal
HIV prevalence drives the paediatric case rate.15 16
Eight-two per cent of cumulative MTCTand 62% of cumula-
tive ‘MTCT-or-death’ occurred by 6 months post-delivery, and
approximately 40% of cumulative MTCT was attributable to
52.4
55.7 56.9















6 weeks 3 month 6 months 9 months 12 months 15 months 18 months
Maternal current ART use Any breastfeeding Nevirapine Infant
Figure 2 Weighted percentage of maternal ART-use, infant feeding
practices and infant nevirapine use amongmothers with consecutive follow-





















Flat line represents 
2.6% MTCT at 6-weeks
Footnote: Dotted lines are upper and lower limits of the 95% confidence interval
Figure 3 Postnatal MTCT cumulative incidence curve (%) with 95% CI.
MTCT, mother-to-child transmission of HIV.
Table 1 Estimation of interval (weeks)-specific MTCT percentage by corresponding reported breastfeeding practice and start of ART initiation

























































































































































*Reports the number and percentage prevalence of each reported type of feeding practice during each time point.
#MTCT = number of infants infected with HIV; % MTCT reports the percentage MTCT within this feeding group at each time point; (–): numbers very small; thus, CI not generated.
MTCT, mother-to-child transmission of HIV.
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postnatal MTCT in the context of 64.1% breastfeeding preva-
lence at 6 weeks, decreasing to 29.6% at 6months. Consequently,
strengthening routine maternal and child primary healthcare,
including breastfeeding support, viral suppression for WLHIV
and early infant HIV testing for HEI will be pivotal to improving
infant HIV-free survival henceforth.17
With 6.3% cumulative ‘MTCT or death’, 93.7% of HEI
remaining in follow-up were alive and HIV-free by 18 months.
Our study demonstrated a marked improvement in HIV-free
survival compared with the 77.7% (95% CI 72.5% to 87.0%)
HIV-free survival at 24 months measured in two South African
sites in the era of single-dose NVP.18 Our findings were similar to
the 91.9% (95%CI 90.3% to 93.3%)HIV-free survival measured
at 9–14 months in a nationally representative community-based
study conducted prior to PMTCT Option B+ implementation in
Rwanda, a low HIV-prevalence setting.19 Our data thus demon-
strate the impact of PMTCT Option A and B on 18-month
MTCT and HIV-free survival in a high HIV-prevalence setting.
These successes were achieved despite gaps in coverage of mater-
nal ART (<60% at 18 months) and infant NVP prophylaxis
among breastfed infants (73% at 6 months and 22.2% at 18
months), and in the context of declining breastfeeding prevalence.
Our findings demonstrate lower early and final MTCTcompared
with Swaziland (2–3% at 6 weeks post-delivery, increasing to
12–15% at 18 months) and Zimbabwe 8.8% (95% CI 6.9% to
11.1%) at 9–18 months in 201120 21 and 7% at 18 months in
2013–2014.22 Transmission in Zimbabwe ranged from 3% with
preonception maternal ART-initiation to 19.4% with no maternal
or infant antiretroviral exposure. We did not measure maternal
viral load or gather detailed information on maternal ART; thus,
the relative contributions of breastfeeding, ARTandmaternal HIV
are difficult to disentangle.23
Although infant NVP use among breastfeeding infants
decreased to 22% by 18 months, extended NVP use among
breastfeeding infants whose mothers were not on ART was
96.7%, at 3 months, decreasing to just below 70% by 12 months.
Our low (5%) 18-month MTCT may be the result of low breast-
feeding prevalence and high extended NVP coverage among
breastfeeding infants whose mothers were not on ART in the
first 6 months of life.2 4 24 25 Our finding of postnatal MTCT
among mothers who reported not breastfeeding may represent
missed intrauterine or intrapartum infections, given that HIV
diagnostic tests have lower sensitivity with increasing infant
exposure to maternal ART26 or dynamic feeding practices post-
natally. This, together with declining infant NVP prophylaxis
among breastfed infants, illustrates a potential role for comple-
mentary preventative interventions such as neutralising antibo-
dies for breastfeeding infants, which need investigation.
EBF or MBF, in the context of maternal ARTand infant NVP
use, was not significantly associated with an increased risk of
‘MTCT-or-death’, reinforcing breastfeeding as a child survival
strategy in the context of maternal ART-use and viral suppres-
sion, validating the 2016 WHO update on HIV and infant
feeding.27 The latter emphasises the importance of retention in
care for mothers and babies and monitoring virologic
suppression.27 The lack of protective association between post-























Incidence of MTCT-or-death after the 6-week time point
Footnote: Dotted lines – upper and lower limit of 95% confidence intervals 
Figure 4b Cumulative Incidence curve of postnatal MTCT-or-death






































Cumulative incidence of MTCT-or-death including 6-week time point
Footnote: Dotted lines – upper and lower limit of 95% confidence intervals 
Figure 4a Cumulative incidence curve (%) ofMTCT-or-death including the
6-week time point with 95% CI. MTCT, mother-to-child transmission of HIV.
Table 2 Survey Cox regression model of factors associated with




(95% CI) P value
Adjusted HR
(95% CI) P value
Maternal
Maternal age 1.0 (0.9–1.1) 0.82 1.0 (1.0–1.0) 0.70
Married/cohabiting mother 1.1 (0.5–2.2) 0.81 0.9 (0.6–1.3) 0.47
Maternal ART-use† 0.6 (0.3–1.2)† 0.15 0.8 (0.6–1.2)† 0.32
Socio-economic (at baseline)
No transport available to
clinic
0.6 (0.3–1.1) 0.09 0.9 (0.6–1.4) 0.64
Unpiped water 1.8 (0.8–4.1) 0.15 1.4 (0.9–2.2) 0.16
No flush toilet 0.7 (0.3–1.3) 0.25 0.9 (0.6–1.4) 0.90
Did not run out of food 1.0 (0.4–2.3) 0.95 1.7 (1.0–2.9) 0.06
No refrigerator 1.0 (0.3–3.2) 1.00 1.7 (1.1–2.9) 0.03
Infant
EBF ref: formula 2.3 (1.0–5.2) 0.049 0.9 (0.6–1.3)† 0.55
MF ref: formula 3.7 (1.2–11.4) 0.03 1.6 (0.8–2.9)† 0.18
Infant NVP use at 6 weeks 0.4 (0.1–1.0) 0.06 0.4 (0.2–0.9) 0.02
Infant male gender 0.8 (1.0–5.6) 0.06 1.3 (0.8–1.9) 0.24
No other infant medication
use, other than NVP
0.7 (0.3–1.8) 0.43 1.3 (0.7–2.4) 0.45
Health service access/quality




2.2 (1.0–4.7) 0.04** 1.5 (0.9–2.4) 0.09
Mother did not receive ARV
during pregnancy
1.2 (0.6–2.4) 0.56 1.2 (0.8–1.8) 0.37
Birth location not in a clinic 0.6 (0.4–1.9) 0.77 1.1 (0.7–1.6) 0.70
*A total of 2240 observations used with 34 events. Wald statistic <0.0001; 2533
observations used with 96 events; Wald statistic=0.0002.
†Time-dependent covariate. All remaining variables were from the baseline interview.
‡Excludes infections detected at 6 weeks post-delivery
**p<0.05.
ART, antiretroviral therapy; ARV, antiretroviral drug; MTCT, mother-to-child transmission of
HIV,NVP, nevirapine, EBF—exclusive breastfeeding, RTHB—Road-to-Health
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ART-use (regardless of feeding practice) could relate to poor
adherence and low coverage of ART postnatally.28
Lastly, no documentation of infant HIV exposure status on
patient-held records, and ‘mother not tested for CD4 cell
count’ significantly increased the risk of postnatal MTCT,
reminding us that biomedical interventions need to be implemen-
ted alongside health system strengthening initiatives.29
Limitations and strengths
We may have underestimated MTCT and MTCT-or-death as
recruitment began at first immunisation visit, excluding early
infant deaths, and being a close cohort, we excluded mothers
with incident HIV infections postnatally. Furthermore, we used
the WHO standard for HIV diagnosis at 18 months (rapid HIV
testing), which, under field conditions, has a lower sensitivity for
detecting recent infection than PCR. We did not have access to
maternal viral loads, to investigate MTCT by viral load. The
small number of postnatal HIV infections (n=34) limited exten-
sive modelling. Although we account for two types of lost to
follow-up (no consent and consent but no show) by inverse
proportional weighting, these missing information may have
underestimated MTCT. Notwithstanding this, we assessed
national PMTCTeffectiveness in a high HIV prevalence setting,
which few high HIV-prevalence countries have been able to
measure. The cohort was drawn from a nationally representative
sample with high rates of consent (94.1%), survival tracing (96%)
and 71% follow-up to 18 months. The analyses are weighted for
live births, non-consent and loss to follow-up, thus reducing bias
and allowing extrapolation to national level. While there may be
considerable attenuation of the study group with differential
non-inclusion and considerable amount of censoring, limiting
the denominator used in the later events, our findings are com-
parable with other studies.
CONCLUSIONS
While the WHO target of <5% final MTCTwas met, the esti-
mated case rate (1290) was 25 times above target. Systems are
especially needed to optimise the health of HEUs from deprived
settings (eg, no refrigerator) in the first 6 months post-delivery.
Breastfeeding was not a significant risk factor for ‘MTCT-or-
death’. Given that we described transmissions among children
with no reported breastfeeding, ART initiation should be fast-
tracked in mothers newly diagnosed with HIV infection postna-
tally even if they do not report breastfeeding.
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What is already known on this subject
► Most global plan priority countries do not routinely monitor
long-term national PMTCT programme effectiveness; they rely on
modelling.
► In 2009, Ruton et al estimated HIV-free survival in Rwanda, at
9–24 months as 91.9% (95% CI 90.4% to 93.3%) following
a nationally representative household survey (n=1448 HIV-
exposed uninfected infants), conducted when single-dose
nevirapine was policy.
► In 2012, Buzdugan et al surveyed 1081 mother-HIV exposed infant
pairs in Zimbabwe, from 157 randomly selected health facilities
within 5 of the 10 provinces. 9- to 18-month MTCT ranged from
8.8% (95% CI 6.9% to 11.1) to 10.1% (95% CI 7.7% to 13.1%)
and HIV-free survival ranged from 89.8% (95% CI 86.8 to 92.2) to
90.9% (95% CI 88.7% to 92.7%), depending on how PMTCT
exposure was defined.
► In 2013, Dinh et al measured national MTCT before scale up to
PMTCT Option B+ (n=1172 mother–HIV-exposed infant pairs at
18 months). Participants were recruited from 151 immunisation
clinics nationally. MTCT was 7% by 18 months, with 50% MTCT
measured by 6 weeks, and an additional 25% by 6 months. Post-
delivery MTCT was lowest (1.8%) among mothers who started
ART preconception (1.2%) versus pregnancy (2.7%). HIV-free
survival was not estimated in this analysis.
► As far we know, no other studies have been undertaken to assess
long-term national PMTCT effectiveness.
What this study adds
► We demonstrate attainment of the first impact criteria for final
MTCT elimination (MTCT <5%) in South Africa, by 2014. This was
achieved notwithstanding 60% maternal ART coverage at 18
months, and 72% and 22% infant nevirapine propylaxis coverage
among breastfeeding infants at 6 and 18-months, respectively.
► The case rate was estimated as 1290 which is 25 times higher than
the global target, demonstrating that South Africa is not on track
to eliminate MTCT.
► We also measured 93.7% HIV-free survival (95% CI 92.7% to
94.5%), and 1.7% postnatal MTCT after 6 weeks through 18months.
► Breastfeeding was not a risk factor for ‘MTCT-or-death’,
illustrating the continued protective effect of breastfeeding under
antiretroviral cover, in countries with high background mortality.
► We also demonstrate the importance of regular follow-up and care
during the first 6 months of life as 82% of cumulative (6 weeks to
18 months) MTCT and 62% of cumulative ‘MTCT-or-death’
occurred by 6 months post-delivery.
Policy implications
► Our findings substantiate the 2016 WHO updated guidance to
harmonise infant feeding recommendations between HIV-positive
and HIV-negative women under ART cover and viral suppression.
► Our findings illustrate the critical need to (i) strengthen the routine
postnatal care platform in the first 6 months of life, including
breastfeeding under ART cover and maternal viral suppression; (ii)
implement regular infant HIV testing in the first 6 months of life, or
at least at 6-months, rather than waiting until 18 months and (iii)
know maternal blood results, and document maternal HIV status
on patient-held health cards.
► Inter-sectoral interventions are needed to improve socio-economic
status, and special care and attention is needed for HIV-exposed
uninfected infants from deprived backgrounds (no refridgerator)
to optimise their HIV-free survival.
Goga AE, et al. J Epidemiol Community Health 2020;74:1069–1077. doi:10.1136/jech-2019-213453 1075





















6University of the Western Cape, Bellville, South Africa
7UNICEF, New York, USA
8Centre for HIV and STI, National Institute for Communicable Diseases, Johannesburg,
South Africa
9Department of Paediatrics and Child Health, University of the Witwatersrand Faculty
of Health Sciences, Johannesburg, South Africa
10Division of Virology and Communicable Diseases, University of the Witwatersrand,
Johannesburg-Braamfontein, South Africa
11Medical Research Council of South Africa, Tygerberg, South Africa
12UNICEF, Abuja, Nigeria
13National Department of Health, Pretoria, South Africa
14Center for Global Health, CDC, Atlanta, Georgia, USA
Acknowledgements The authors thank the funders and collaborators listed below,
and mothers and infants enrolled in the study.
Contributors AEG—principal investigator (PI) on the study—conceptualised the
paper, oversaw all fieldwork, interpreted data, provided the theoretical background
to guide statistical analysis, drafted the paper, incorporated all co-author and
CDC comments, finalised the paper and approved the final version. CJL—hief
statistician—calculated sample size, conducted all analyses, wrote statistical
analysis section, contributed to all versions of the paper and approved the final
version. DJJ—PI on the study, was in charge of the mobile technology used to
gather data, assisted with data interpretation, commented on all versions of the
paper and approved the final version. VR assisted with data management and
interpretation, commented on all versions of the paper and approved the final
version. NN conducted data management and cleaning, assisted with data
interpretation, commented on all versions of the paper and approved the final
version. GGS assisted with training on dried blood spots drawing and with systems
to return results, guided data analysis, and interpretation, commented on all
versions of the paper and approved the final version. AP oversaw all laboratory work
in accordance with standardised operating procedures, write the laboratory section
of the paper, commented on all versions of the paper and approved the final version.
WC assisted with data interpretation, commented on all versions of the paper and
approved the final version of the paper. SB assisted with data interpretation,
commented on all versions of the paper and approved the final version of the paper.
NM—logistics manager on the study—assisted with data interpretation,
commented on all versions of the paper and approved the final version of the paper.
TR—provincial coordinator on the study—assisted with data interpretation,
commented on all versions of the paper and approved the final version of the paper.
VM—provincial coordinator on the study—assisted with data interpretation,
commented on all versions of the paper and approved the final version of the paper.
YS oversaw the development of the mobile technology systems for data collection
and functioning thereof, assisted with data interpretation, commented on all
versions of the paper and approved the final version of the paper. YP assisted with
conceptualisation of the study and data interpretation, commented on all versions of
the paper and approved the final version of the paper. T-HD—PI on the study and is
senior author on the paper—assisted with setting up systems for cohort monitoring,
assisted with data management and data interpretation, commented on all versions
of the paper and approved the final version.
Funding This study was primarily funded by the US President’s Emergency
Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and
Prevention (CDC) under terms of cooperative agreement number
1U2GPS001137 and 1U2GGH001150. UNICEF, the South African Medical
Research Council, the South African National AIDS Council, the National
Institute of Communicable Diseases, the National Department of Health and
the Global Fund (through the National Department of Health) also provided
funding support through collaboration agreements. The South African National
Research Foundation supported D Jackson during the time of this study.
Disclaimer The findings and conclusions in this report are those of the authors and
do not necessarily represent the official position of the funding agencies.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially, and
license their derivative works on different terms, provided the original work is properly
cited, appropriate credit is given, any changes made indicated, and the use is non-
commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iD
Ameena Ebrahim Goga http://orcid.org/0000-0002-2394-6486
REFERENCES
1 Goga AE. Infant feeding and HIV: towards a new implementation plan for minimising




2 Kumwenda NHD, Mofenson L, Thigpen M, et al. Extended antiretroviral prophylaxis to
reduce breastmilk HIV-1 transmission. N Engl J Med 2008;359:119–29.
3 Shapiro R, Hughes M, Ogwu A, et al. Antiretroviral regimens in pregnancy and
breast-feeding in Botswana. N Engl J Med 2010;362:2282–94.
4 Six week extended dose nevirapine (SWEN) Study team, et al. Extended dose nevir-
apine at 6 weeks of age for infants to prevent HIV transmission via breastfeeding in
Ethiopia, India and Uganda: an analysis of 3 randomised controlled trials. Lancet
2008;372:300–13.
5 World Health Organisation. Use of antiretroviral drugs for treating pregnant women
and preventing HIV infection in infants. Apr 2012.
6 Moyo F, Haeri Mazandarani A, Barron P, et al. Introduction of routine birth testing in
the South African national consolidated guidelines. Paediatric Infect Dis J 2017.
7 Goga A, Dinh T, Jackson D, et al. First population-level effectiveness evaluation of
a national programme to prevent HIV transmission from mother to child, South Africa.
J Epidemiol Community Health 2015;69:240–8.
8 Goga A, Chirinda W, Ngandu N, et al. Closing the gaps to eliminate mother-to-child
transmission of HIV (MTCT) in South Africa: understanding MTCT case rates, factors
that hinder the monitoring and attainment of targets, and potential game changers.
S Afr Med J 2018;108(Suppl 1):17.
9 UNAIDS. Global plan progress report. 2015. Available http://www.unaids.org/en/resources/
documents/2015/JC2774_2015ProgressReport_GlobalPlan (accessed 1 Nov 2019)
10 World Health Organisation. Global guidance on criteria and processes for
validation: elimination of mother-to-child transmission of HIV and syphilis. 2014.
Available http://www.who.int/hiv/pub/emtct-validation-guidance/en/ (accessed
1 Nov 2019)
11 Goga A, Dinh T, Jackson D, et al. Population-level effectiveness of maternal antire-
troviral treatment initiation before or during the first trimester and infant antiretroviral
prophylaxis on early mother-to-child transmission of HIV, South Africa: implications for
eliminating MTCT. J Glob Health 2016;6. Available http://www.jogh.org/documents/
issue201602/jogh-06-020405.pdf
12 National Department of Health and SANAC. Clinical guidelines: PMTCT (prevention of
mother-to-child transmission). 2010. Available https://www.fidssa.co.za/Content/
Documents/PMTCT_Guidelines.pdf (accessed 1 Nov 2019)
13 National Department of Health. The South African antiretroviral treatment
guidelines 2013: PMTCT guidelines revised march 2013. Available https://sahiv
soc.org/Files/2013%20ART%20Treatment%20Guidelines%20Final%2025%
20March%202013%20corrected.pdf (accessed 1 Nov 2019)
14 Woldesenbet S, Kufa T, Lombard C, et al. The 2017 national antenatal sentinel HIV
survey, South Africa. Pretoria: National Department of Health, 2019.
15 Goga A, Singh Y, Jackson D, et al. Is elimination of vertical transmission of HIV in high
HIV prevalence settings achievable? Br Med J 2019;364.
16 Goga AE, Dinh T-H, Essajee S, et al. What will it take for the global plan priority
countries in sub-Saharan Africa to eliminate mother-to-child transmission of HIV? BMC
Infect Dis 2019;19:783.
17 Violari A, Cotton M, Gibb D, et al. Early antiretroviral therapy and mortality among
HIV-infected infants. N Engl J Med 2008;359:2233–44.
18 Stringer J, Stinson K, Tih P, et al. Measuring coverage in MNCH: population HIV-free
survival among children under two years of age in four African countries. PLoS Med
2013;10:e1001424.
19 Ruton H, Mugwaneza P, Shima N, et al. HIV-free survival among nine- to 24-month-old
children born to HIV-positive mothers in the Rwandan national PMTCT programme: a
community-based household survey. J Int AIDS Soc 2012;15:4.
20 Buzdugan R, McCoy S, Watadzaushe C, et al. Evaluating the impact of
Zimbabwe’s prevention of mother-to-child HIV transmission program: population-
level estimates of HIV-free infant survival pre-option A. PLoS One
2015;10:e0134571.
21 UNAIDS. On the fast track to an AIDS free generation: the incredible journey of
the global plan towards the elimination of new HIV infections among children by
2015 and keeping their mothers alive. Geneva: UNAIDS. 2016. Available http://
www.aidsdatahub.org/fast-track-aids-free-generation-unaids-2016 (accessed 1
Nov 2019).
22 Dinh T, Mushavi A, Shiraishi R, et al. Impact of timing of antiretroviral treatment and
birth weight on mother-to-child human immunodeficiency virus transmission: findings
from an 18-month prospective cohort of a nationally representative sample of mother:
infant pairs during the transition from option a to option B+ in Zimbabwe. Clin Infect
Dis 2017;66:576–85.
23 World Health Organisation. Infant and young child feeding database. 2017. Available
http://www.who.int/nutrition/databases/infantfeeding/countries/swz.pdf?ua=1 (accessed
1 Nov 2019)
24 Jamieson D, Chasela C, Hudgens M, et al. Maternal and infant antiretroviral regimens
to prevent postnatal HIV transmission: 48 weeks follow-up of the BAN randomised
controlled trial. Lancet 2012;379:2449–258.
1076 Goga AE, et al. J Epidemiol Community Health 2020;74:1069–1077. doi:10.1136/jech-2019-213453





















25 Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with
zidovudine and single-dose nevirapine prophylaxis during pregnancy and
breastfeeding for prevention of mother-to-child transmission of HIV-1
(Kesho Bora study): a randomised controlled trial. Lancet Infect Dis
2011;11:171–80.
26 Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for
early diagnosis of perinatal HIV-1 infection during antiretroviral prophylaxis. J Pediatr
2012;160:60–6.
27 World Health Organisation, UNICEF. 2016 guideline update on HIV and infant feeding.
Geneva, 2016.
28 Nachega J, Uthman O, Anderson J, et al. Adherence to antiretroviral therapy during
and after pregnancy in low-income, middle-income, and high-income countries. AIDS
2012;26:2039–52.
29 Sprague C, Chersich M, Black V. Health system weaknesses constrain access to PMTCT
and maternal HIV services in South Africa: a qualitative enquiry. AIDS Res Ther 2007
Nov 22;4:27. 2011;8:10.
Goga AE, et al. J Epidemiol Community Health 2020;74:1069–1077. doi:10.1136/jech-2019-213453 1077















ealth: first published as 10.1136/jech-2019-213453 on 26 S
eptem
ber 2020. D
ow
nloaded from
 
